BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include peramivir injection, an intravenous neuraminidase inhibitor sold under the RAPIVAB, RAPIACTA, and PERAMIFLU names for acute uncomplicated and seasonal influenza, as well as ORLADEYO, an oral serine protease inhibitor used in HAE. The company’s development pipeline includes BCX17725 for netherton syndrome, Avoralstat for diabetic macular edema, Navenibart for HAE, and STAR-0310 for atopic dermatitis, with several programs in early-stage clinical testing. BioCryst also has collaboration and in-licensing relationships with organizations including Torii Pharmaceutical, Shionogi, Green Cross, NIAID, BARDA, the U.S. Department of Health and Human Services, and several academic institutions. Founded in 1986, the company is headquartered in Durham, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BCRX
|
$8.49
|
11.0% Upside
|
Fair
|
$20.55
|
168.6% Upside
|
Bargain
|
Great
|
0.0%
|
2.1x
|
1.955 B
|
2.439 B
|
30.0%
|
87.0%
|
0.6
|
-97.1%
|
